Vascular News and Research

RSS

Fifth gene defect, 47 DNA regions linked to thoracic aortic disease: Researchers

Discovery of a fifth gene defect and the identification of 47 DNA regions linked to thoracic aortic disease are the subject of studies released this month involving researchers at The University of Texas Health Science Center at Houston.

19 Nov 2010

ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium

ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's IMGN388 anticancer compound at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany.

19 Nov 2010

DoD recommends funding for Synta's STA-9584 for prostate cancer study

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Department of Defense (DoD) has recommended STA-9584, a novel vascular disrupting agent (VDA) currently in pre-clinical development at Synta, be funded for study in advanced prostate cancer.

19 Nov 2010

Study compares effect on HT status in mid, late life on dementia risk

Compared to women never on hormone therapy, those taking hormone therapy only at midlife had a 26 percent decreased risk of dementia; while women taking HT only in late life had a 48 percent increased risk of dementia, according to Kaiser Permanente researchers.

19 Nov 2010

OXiGENE updates data on FALCON trial for non-small cell lung cancer

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT(TM) (CA4P) in patients with non-small cell lung cancer (NSCLC).

19 Nov 2010

Aastrom announces interim analysis of Phase 2b RESTORE-CLI clinical trial for treatment failure

Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that an interim analysis of all 86 patients enrolled in the company's Phase 2b RESTORE-CLI clinical trial shows that the study achieved both its primary safety endpoint and primary efficacy endpoint of time to first occurrence of treatment failure.

19 Nov 2010

St. Jude Medical completes acquisition of AGA Medical

St. Jude Medical, Inc. today announced that it has successfully completed its acquisition of AGA Medical Holdings, Inc.

19 Nov 2010

Study finds adverse long term health effects of E coli infection

People who contract gastroenteritis from drinking water contaminated with E coli are at an increased risk of developing high blood pressure, kidney problems and heart disease in later life, finds a study published online in the British Medical Journal.

19 Nov 2010

BMEYE ccNexfin receives FDA clearance

BMEYE B.V., the innovators of combined totally noninvasive, beat-to-beat blood pressure and cardiac output monitoring announces FDA clearance and the United States launch of the BMEYE ccNexfin-the first totally noninvasive cardiovascular monitor with blood pressure, cardiac output, and Masimo rainbow SET Pulse CO-Oximetry measurements.

19 Nov 2010

Clinical trial results of ArterX presented at Veith Meeting

US clinical trial results for Tenaxis' investigational vascular surgical sealant, ArterX, were presented today at the Veith Meeting in New York. William M. Stone, MD of the Mayo Clinic, Scottsdale AZ reported a more than 20% margin of improvement for ArterX Surgical Sealant in the sealing of vascular suture lines compared with a control group featuring a commercially available gelatin foam/thrombin combination.

19 Nov 2010

Pericyte cells become key players in shaping blood flow in the brain

Cells in the brain called pericytes that have not been high on the list of targets for treating diseases like Alzheimer's may play a more crucial role in the development of neurodegenerative diseases than has been realized.

18 Nov 2010

Gore launches new internet cloud-based 3D advanced visualization and decision support system

W. L. Gore & Associates today announced the introduction of the GORE® 3D Imaging System, a new internet cloud-based 3D advanced visualization and decision support system that will change the paradigm of pre-case planning. The revolutionary new system, which is on exhibit at the VEITHsymposium (37th Annual Symposium on Vascular and Endovascular Issues), reflects Gore's ongoing commitment to supporting physicians in making informed treatment decisions.

18 Nov 2010

Researchers unveil novel oncogene associated with uveal melanoma

An international, multi-center study has revealed the discovery of a novel oncogene that is associated with uveal melanoma, the most common form of eye cancer.

18 Nov 2010

Researchers are revolutionizing treatment of cardiovascular disease through regenerative stem cell therapy

Northwestern Medicine physician researchers are revolutionizing treatment of cardiovascular disease by utilizing patients' own stem cells to regenerate heart and vascular tissue.

18 Nov 2010

Regado presents poster on REG3 at AHA Scientific Sessions meeting

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Steven L. Zelenkofske, D.O., F.A.C.C., Senior Vice President and Chief Medical Officer, and Chris Rusconi, Ph.D., Senior Vice President and Chief Scientific Officer, presented a poster about REG3 at the AHA Scientific Sessions meeting.

18 Nov 2010

Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting

Sangamo BioSciences, Inc. announced today the presentation of Phase 2 clinical data from its ZFP Therapeutic program to develop SB-509, a zinc finger protein transcriptional activator (ZFP-TF) of the vascular endothelial growth factor (VEGF)-A gene as a treatment for ALS.

17 Nov 2010

AACN endorses intraosseous vascular access

Recognizing that IV use is not always optimal to provide patients with fluids and medications, the American Association of Critical-Care Nurses (AACN) recently endorsed a consensus paper that recommends intraosseous (IO) vascular access in a variety of healthcare settings.

17 Nov 2010

Scientists investigate new class of drugs for treating kidney failure

Scientists are learning more about how protein gets in the urine when the kidneys begin to fail and how a new drug blocks it.

17 Nov 2010

Cholesterol-lowering statin therapy benefits patients with calcium buildup in arteries

Rolling back suggestions from previous studies, a Johns Hopkins study of 950 healthy men and women has shown that taking daily doses of a cholesterol-lowering statin medication to protect coronary arteries and ward off heart attack or stroke may not be needed for everyone.

17 Nov 2010

MedImmune to present data on oncology portfolio at two medical congresses in Europe and the U.S.

Today, MedImmune announced that researchers will present data from its oncology portfolio, including new clinical data, at two upcoming medical congresses in Europe and the United States.

17 Nov 2010

Vascular News and Research

Fifth gene defect, 47 DNA regions linked to thoracic aortic disease: Researchers

ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium

DoD recommends funding for Synta's STA-9584 for prostate cancer study

Study compares effect on HT status in mid, late life on dementia risk

OXiGENE updates data on FALCON trial for non-small cell lung cancer

Aastrom announces interim analysis of Phase 2b RESTORE-CLI clinical trial for treatment failure

St. Jude Medical completes acquisition of AGA Medical

Study finds adverse long term health effects of E coli infection

BMEYE ccNexfin receives FDA clearance

Clinical trial results of ArterX presented at Veith Meeting

Pericyte cells become key players in shaping blood flow in the brain

Gore launches new internet cloud-based 3D advanced visualization and decision support system

Researchers unveil novel oncogene associated with uveal melanoma

Researchers are revolutionizing treatment of cardiovascular disease through regenerative stem cell therapy

Regado presents poster on REG3 at AHA Scientific Sessions meeting

Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting

AACN endorses intraosseous vascular access

Scientists investigate new class of drugs for treating kidney failure

Cholesterol-lowering statin therapy benefits patients with calcium buildup in arteries

MedImmune to present data on oncology portfolio at two medical congresses in Europe and the U.S.

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News